How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study Academic Article uri icon

Overview

MeSH Major

  • Breast Neoplasms
  • Patient Participation
  • Practice Guidelines as Topic
  • Precision Medicine

abstract

  • Nearly 70 % of the N+ patients were eligible for SLNB after NAC. For 48 %, ALND was avoided, supporting the role of NAC in reducing the need for ALND among patients presenting with nodal metastases.

publication date

  • October 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5070651

Digital Object Identifier (DOI)

  • 10.1245/s10434-016-5246-8

PubMed ID

  • 27160528

Additional Document Info

start page

  • 3467

end page

  • 3474

volume

  • 23

number

  • 11